Last reviewed · How we verify
NCT05761379
Clinical Study of Light Therapy to Control Myopia Progression in Children
NA trial testing Photobiomodualtion Therapy in Myopia, Progressive in 83 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Beijing Airdoc Technology Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 83 |
| Start date | 28 March 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Photobiomodualtion Therapy
- Single vision spectacles for correction myopia
Conditions studied
- Myopia, Progressive — all drugs for Myopia, Progressive →
Sponsor
Beijing Airdoc Technology Co., Ltd.
Who can join
Adults 6 to 16, any sex, with Myopia, Progressive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Low-lever red light therapy (LLLT) has been used to control myopia progression in China for a few years besides amblyopia therapy for a few decades. This study is to test the efficacy of PBM therapy to myopia children as well as to compare two types of PBM therapy to control myopia progression within one month.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05761379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia, Progressive
Currently open trials in the same condition.
- NCT06927388 — Myopia Progression With Freeform Myopia Control Spectacles · NA · active not recruiting
- NCT07055815 — Impact of Digital Screen Time in Progression of Myopia in Children · active not recruiting
- NCT06389110 — Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elo · Phase 3 · recruiting
- NCT06647160 — Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control · NA · active not recruiting
- NCT06520124 — Stellest Lens Wear in Adult Progressing Myopes · NA · active not recruiting
Other Beijing Airdoc Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT06059521 — Software Refraction With Mobilerone Versus Retinoscopy · NA · recruiting
- NCT05881655 — Slow Myopia Progression With Different Irradiance Light · NA · unknown
- NCT05811598 — Real Word Study on Myopia Control With Repeated Red Light Therapy for Ages of 3~6 Years Old · NA · unknown
- NCT05756959 — Myopia Control Combined PBM With Myopic Defocus Lens in Children · NA · recruiting
- NCT06088225 — Myopia Preventing With Distance-image Screen · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05761379 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Airdoc Technology Co., Ltd.
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing